^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

CHD1 deletion

i
Entrez ID:
Related biomarkers:
3ms
Frequent CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression. (PubMed, NPJ Precis Oncol)
This was consistent with the moderate increase of olaparib and talazoparib sensitivity with several CHD1 deficient cell lines showing talazoparib sensitivity in the clinically relevant concentration range. CHD1 loss may contribute to worse disease outcome in African American men.
Journal • PARP Biomarker
|
RAD51 (RAD51 Homolog A) • CHD1 (Chromodomain Helicase DNA Binding Protein 1)
|
CHD1 deletion • RAD51 mutation
|
Lynparza (olaparib) • Talzenna (talazoparib)
almost2years
CHD1 deletion stabilizes HIF1α to promote angiogenesis and glycolysis in prostate cancer. (PubMed, Asian J Androl)
Functional analysis showed that CHD1 deletion promoted angiogenesis and glycolysis, possibly through HIF1α target genes. Taken together, these findings indicate that CHD1 deletion enhances HIF1α expression through PHD2 downregulation and therefore promotes angiogenesis and metabolic reprogramming in PCa.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • VHL (von Hippel-Lindau tumor suppressor) • CHD1 (Chromodomain Helicase DNA Binding Protein 1)
|
CHD1 deletion • HIF1A expression
over3years
The role of chromodomain helicase DNA binding protein 1 (CHD1) in promoting an invasive prostate cancer phenotype. (PubMed, Ther Adv Urol)
Compared to parental cells, CHD1 KO cells showed a reduction in ECM and adhesion molecules as well as a greater proportion of viable suspension cells when cultured on standard tissue culture plates and on plates coated with laminin, fibronectin or collagen I. CHD1 KO cells showed a decrease in the expression of secreted protein acidic and rich in cysteine (SPARC), matrix metalloproteinase 2 (MMP2), integrin subunit alpha 2 (ITGA2), integrin subunit alpha 5 (ITGA5), integrin subunit alpha 6 (ITGA6), fibronectin (FN1), laminin subunit beta-3 precursor (LAMB3), collagen, tenascin and vitronectin as compared to parental and NT2 cells. These data suggest that in erythroblast transformation specific (ETS) fusion-negative, phosphatase and tensin homolog (PTEN) wildtype PCa, deletion of CHD1 alters cell-cell and cell-matrix adhesion dynamics, suggesting an important role for CHD1 in the development and progression of PCa.
Journal
|
PTEN (Phosphatase and tensin homolog) • SPARC (Secreted Protein Acidic And Cysteine Rich) • MMP2 (Matrix metallopeptidase 2) • FN1 (Fibronectin 1) • CHD1 (Chromodomain Helicase DNA Binding Protein 1) • ITGA5 (Integrin Subunit Alpha 5) • ITGA6 (Integrin, alpha 6)
|
CHD1 deletion • PTEN negative
over3years
Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer. (PubMed, J Clin Invest)
Importantly, the clinical and pathologic features associated with distinct late events at radical prostatectomy were strikingly different; PTEN deletions were associated with increased locoregional stage, while CHD1 deletions were only associated with increased grade, despite equivalent metastatic potential.CONCLUSIONThese findings suggest a paradigm in which specific subtypes of PCa follow distinct pathways of progression, at both the molecular and clinical levels. Therefore, the interpretation of common clinical parameters such as locoregional tumor stage may be influenced by the underlying tumor lineage, and potentially influence management decisions.FUNDINGProstate Cancer Foundation, National Cancer Institute, Urology Care Foundation, Damon Runyon Cancer Research Foundation, US Department of Defense, and the AIRC Foundation.
Clinical • Journal
|
PTEN (Phosphatase and tensin homolog) • SPOP (Speckle Type BTB/POZ Protein) • CHD1 (Chromodomain Helicase DNA Binding Protein 1)
|
PTEN deletion • SPOP mutation • CHD1 deletion • ERG overexpression
over3years
[VIRTUAL] Targeting the Tumor Microenvironment (CSI-FCS 2020)
We determined that CHD1 deletion causes major remodeling of the TME, and established CHD1/IL-6 as a major regulator of the immunosuppressive TME in PTEN-deficient prostate cancer. These observations of cancer cell/immune cell crosstalk across cancer types open the possibility of new strategies to enhance the effectiveness of current immune cell inhibitor therapies by combination with TME-targeted therapies.
KRAS (KRAS proto-oncogene GTPase) • PTEN (Phosphatase and tensin homolog) • IL6 (Interleukin 6) • CHD1 (Chromodomain Helicase DNA Binding Protein 1)
|
CHD1 deletion